The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention.

Korean Circ J · 2024 · PMC11040264 · PMID 38654565

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Within each CHADS-P2A2RC risk stratum, the 2 antiplatelet groups did not significantly differ in the occurrence of any endpoint (MACCE, all-cause death, MI, or stroke), and the interaction term did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.